Project Grant R00HL177828
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$445K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The federal Project Grant award R01HL174794, issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $959,457.45 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the transcriptional regulation of myelopoiesis. The award supports a comprehensive, 5-month research project aimed at defining how growth factor and cytokine signaling regulates the expression of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $688,800 in funding to Albert Einstein College of Medicine to conduct research on the mechanisms of RUNX1 transcriptional control in hematopoiesis. The goal is to define how RUNX1, a critical transcription factor, cooperates with other factors to regulate gene expression programs and facilitate hematopoietic lineage development....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $435,804 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to elucidate the mechanistic basis for the selective advantage of the acquired DDX41R525H mutation in hematopoietic stem cells (HSCs) of patients with germline DDX41 mutations, who develop myelodysplastic syndrome (MDS) and related myeloid malignancies. The...
This $773,257 federal project grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting research to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs) at St. Jude Children's Research Hospital. The research leverages novel live-cell imaging tools developed by the grantee to track and quantify single HSC behaviors and marker expression...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms by which mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) disrupt cardiac metabolism and lead to cardiomyopathy. The $549,796 award to Cedars-Sinai Medical Center aims to examine how these AML-related genetic mutations impact oxidative metabolism, epigenetic...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $445,000.00 to The Children's Hospital of Philadelphia Research Institute to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The key objectives are to: Characterize the role of NETs in immune homeostasis and host defense, exploring how impaired NET formation impacts...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The $179,280 award, spanning 2 years from September 2024 to August 2026, will investigate how early life nutritional stress, such as high-fat diets, impacts the development and function of neutrophils - a key immune cell type - and its implications for the severity of sickle cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $735,085 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Case Western Reserve University (CWRU) to leverage the heat shock transcription factor 1 (HSF1) to transform detrimental age-related clonal hematopoiesis (CH) into a state favoring normal blood cell production. The research aims to understand how deleting HSF1 along with other CH-associated mutations (DNMT3A or TET2) can sustain or enhance...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $380,383 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, awarded on April 21, 2025, supports research to understand and prevent DNA damage in hematopoietic (blood) stem cells, which is critical for maintaining their regenerative capacity. The project aims to dissect the role of aldehyde-metabolizing enzymes in protecting stem cells, uncover novel disease...
This federal Project Grant award of $465,000.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate inflammation-associated autophagy dysfunction in sickle cell disease (SCD). The research aims to elucidate the mechanisms by which tumor necrosis factor-alpha (TNF-α) disrupts the hemostatic balance in SCD by impairing autophagy and mitophagy in platelets and reticulocytes. The award period...